The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden

Abstract

AimsThe epidemiology of congestive heart failure (CHF) is likely to have changed due to changes in demography, risk factors, diagnostic procedures, and medical care. Prevailing information is in part old, incomplete, and to some extent contradictory. We determined the current prevalence, incidence, mortality, and 5-year survival rate of CHF, and possible temporal changes in Sweden. Methods and resultsThis was a cross-sectional study on individual patient data from an administrative health data register in the Stockholm region, Sweden, comprising 2.1 million inhabitants. This contained all recorded diagnoses on all consultations in primary and secondary care (defined as specialist outpatient care), and on all hospitalizations. Prevalence, incidence, and mortality were estimated for the entire Swedish population, adjusted for demographic composition in 2010. The study population consisted of 88 038 patients (51% women). The prevalence was 2.2% (both women and men), the incidence was 3.8/1000 person-years (both women and men), and mortality was 3.2/1000 person-years in women and 3.0/ 1000 person-years in men (P , 0.001); the 5-year survival rate was 48%. Mortality (age adjusted; hazard ratio and 95% confidence intervals) was higher in men, 1.29, 1.24-1.34; P , 0.001. Prevalence remained essentially unchanged from 2006 to 2010, while incidence decreased by 24% (P , 0.001) and mortality by 19% (both women and men; P , 0.001). ConclusionsThe estimated prevalence of CHF in Sweden is 2.2%, incidence 3.8/1000 person-years, and mortality 3.1/1000 personyears. There has been a decrease in incidence and mortality from 2006 to 2010 in both women and men, with no major change in prevalence over time.--

Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland

“…Advances in both the medical and device based treatments, have been associated with improved survival rates in patients with HF in many [17][18][19][20] but not all national registry-based studies. 21 Age-standardized death rates from heart failure have been reported to decrease by 40% in seven European countries between 1987 and 2008.…”

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study

“…This approach was also used in PARADIGM‐HF with 20 key exclusion criteria, in addition to the already strict entry criteria 19. Real‐world patients rarely fit into those tight frames,1, 14, 15, 16, 17, 18 and we have 75% of our HFrEF population who does not meet the entry criteria, but we still have to give them the best treatment possible. Previous studies have shown that between 10% and 66% of real‐world patients managed to fulfil all enrolment criteria from heart failure RCTs 15, 17.…”

“…With a 5 yr survival chance of only 50%, heart failure has a mortality rate similar to that of several cancer diagnoses 1. Therefore, it is a serious and costly disorder.…”

Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden

“…Chronic heart failure (CHF) is a common medical condition affecting 2.2% of the population in Sweden (1). Uncommon in persons aged younger than 50 years, CHF becomes more prevalent with increasing age and affects 6-10% of the population aged 65 years and older (2).…”